The Association of Genetic Polymorphisms With Statin-Induced Myopathy.
Recruitment status was: Recruiting
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Association Analysis Between Single Nucleotide Polymorphisms in Statin-Related Genes and The Incidence of Myopathy Among Statin-Treated Patients|
- genotype of specific genes [ Time Frame: one day ]
- single nucleotide polymorphism [ Time Frame: one day ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||August 2007|
|Estimated Study Completion Date:||January 2008|
Group 1 for the patients with rhabdomyolysis Group 2 for the control without any myopathy
withdraw 5~10mL blood from vein only once during the whole design
Statins are widely prescribed for the patients with hypercholesterolemia.
Though their efficacy in preventing cardiovascular events has been shown by a large number of clinical trials, myotoxic side effects including myopathy or even more severe,rhabdomyolysis are associated with the use of statins.
Because the incidence of myopathy is various among individuals,polymorphism in genes is supposed to be the main factor.
Due to single nucleotide polymorphism in related genes,level of uptake, clearance and metabolism of statins can be seriously different among individuals resulting in various occurrence of myopathy.
Therefore, analytical study in association between SNP of statins-related genes and the incidence of myopathy is such a critical research which can be applied into clinical fields.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00549029
|National Taiwan University Hospital|
|Taipei, Taiwan, 100|
|Study Director:||Yen-Hui Chen, PhD||National Taiwan Univesity College of Medicine|